2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
Carboplatin
9
Pemetrexed
6
Erlotinib Hydrochloride
5
pembrolizumab
3
osimertinib
3
durvalumab
3
camrelizumab
3
Gemcitabine
3
Gefitinib
3
Cisplatin
3
selpercatinib
2
pralsetinib
2
apatinib
2
Radiosurgery
2
taletrectinib
1
sotorasib
1
sintilimab
1
repotrectinib
1
patritumab
1
necitumumab
1
ficlatuzumab
1
exemestane
1
entinostat
1
cobimetinib
1
ceralasertib
1
alectinib
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
Telescopes
1
Radiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Respiratory Tract Diseases
×
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled